% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mhrmann:181329,
      author       = {L. Möhrmann$^*$ and H. J. Huang and D. S. Hong and A. M.
                      Tsimberidou and S. Fu and S. A. Piha-Paul and V. Subbiah and
                      D. D. Karp and A. Naing and A. Krug and D. Enderle and T.
                      Priewasser and M. Noerholm and E. Eitan and C. Coticchia and
                      G. Stoll and L.-M. Jordan and C. Eng and E. S. Kopetz and J.
                      Skog and F. Meric-Bernstam and F. Janku},
      title        = {{L}iquid {B}iopsies {U}sing {P}lasma {E}xosomal {N}ucleic
                      {A}cids and {P}lasma {C}ell-{F}ree {DNA} {C}ompared with
                      {C}linical {O}utcomes of {P}atients with {A}dvanced
                      {C}ancers.},
      journal      = {Clinical cancer research},
      volume       = {24},
      number       = {1},
      issn         = {1078-0432},
      address      = {Philadelphia, Pa. [u.a.]},
      publisher    = {AACR},
      reportid     = {DKFZ-2022-01956},
      pages        = {181 - 188},
      year         = {2018},
      note         = {POF Topic: 317},
      abstract     = {Purpose: Blood-based liquid biopsies offer easy access to
                      genomic material for molecular diagnostics in cancer.
                      Commonly used cell-free DNA (cfDNA) originates from dying
                      cells. Exosomal nucleic acids (exoNAs) originate from living
                      cells, which can better reflect underlying cancer
                      biology.Experimental Design: Next-generation sequencing
                      (NGS) was used to test exoNA, and droplet digital PCR
                      (ddPCR) and BEAMing PCR were used to test cfDNA for
                      BRAFV600, KRASG12/G13, and EGFRexon19del/L858R mutations in
                      43 patients with progressing advanced cancers. Results were
                      compared with clinical testing of archival tumor tissue and
                      clinical outcomes.Results: Forty-one patients had BRAF,
                      KRAS, or EGFR mutations in tumor tissue. These mutations
                      were detected by NGS in $95\%$ of plasma exoNA samples, by
                      ddPCR in $92\%$ of cfDNA samples, and by BEAMing in $97\%$
                      cfDNA samples. NGS of exoNA did not detect any mutations not
                      present in tumor, whereas ddPCR and BEAMing detected one and
                      two such mutations, respectively. Compared with patients
                      with high exoNA mutation allelic frequency (MAF), patients
                      with low MAF had longer median survival (11.8 vs. 5.9
                      months; P = 0.006) and time to treatment failure (7.4 vs.
                      2.3 months; P = 0.009). A low amount of exoNA was associated
                      with partial response and stable disease ≥6 months (P =
                      0.006).Conclusions: NGS of plasma exoNA for common BRAF,
                      KRAS, and EGFR mutations has high sensitivity compared with
                      clinical testing of archival tumor and testing of plasma
                      cfDNA. Low exoNA MAF is an independent prognostic factor for
                      longer survival. Clin Cancer Res; 24(1); 181-8. ©2017
                      AACR.},
      keywords     = {Adult / Aged / Biomarkers, Tumor / Cell-Free Nucleic Acids
                      / ErbB Receptors: blood / ErbB Receptors: genetics /
                      Exosomes / Female / Genetic Testing / Humans / Liquid
                      Biopsy: methods / Male / Middle Aged / Mutation / Neoplasm
                      Grading / Neoplasm Staging / Neoplasms: blood / Neoplasms:
                      diagnosis / Neoplasms: mortality / Patient Outcome
                      Assessment / Proto-Oncogene Proteins B-raf: blood /
                      Proto-Oncogene Proteins B-raf: genetics / Proto-Oncogene
                      Proteins p21(ras): blood / Proto-Oncogene Proteins p21(ras):
                      genetics / Survival Analysis / Biomarkers, Tumor (NLM
                      Chemicals) / Cell-Free Nucleic Acids (NLM Chemicals) / KRAS
                      protein, human (NLM Chemicals) / EGFR protein, human (NLM
                      Chemicals) / ErbB Receptors (NLM Chemicals) / BRAF protein,
                      human (NLM Chemicals) / Proto-Oncogene Proteins B-raf (NLM
                      Chemicals) / Proto-Oncogene Proteins p21(ras) (NLM
                      Chemicals)},
      cin          = {G100},
      ddc          = {610},
      cid          = {I:(DE-He78)G100-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29051321},
      pmc          = {pmc:PMC5754253},
      doi          = {10.1158/1078-0432.CCR-17-2007},
      url          = {https://inrepo02.dkfz.de/record/181329},
}